Exelixis
EXEL
#1697
Rank
HK$77.40 B
Marketcap
HK$271.03
Share price
0.52%
Change (1 day)
63.84%
Change (1 year)
Exelixis, Inc. is an American genomics-based drug discovery company and the producer of Cometriq, a treatment for medullary thyroid cancer.

Exelixis (EXEL) - Cash on Hand

Cash on Hand as of September 2024 : HK$9.25 Billion

According to Exelixis's latest financial reports the company has HK$9.25 Billion in cash and cash equivalents.
A companyโ€™s cash on hand also refered as cash/cash equivalents (CCE) and Short-term investments, is the amount of accessible money a business has.

Exelixis - Cash on Hand chart (from 2000 to 2024)

Cash on Hand by year

Year Cash on Hand Change
2023-12-31HK$7.77 B-23.96%
2022-12-31HK$10.22 B-10.63%
2021-12-31HK$11.43 B22.31%
2020-12-31HK$9.35 B40.92%
2019-12-31HK$6.63 B22.25%
2018-12-31HK$5.42 B79.21%
2017-12-31HK$3.02 B-6.93%
2016-12-31HK$3.25 B151.41%
2015-12-31HK$1.29 B15.7%
2014-12-31HK$1.11 B-40.47%
2013-12-31HK$1.88 B-41.05%
2012-12-31HK$3.18 B111.37%
2011-12-31HK$1.50 B19.19%
2010-12-31HK$1.26 B-19.61%
2009-12-31HK$1.57 B-22.34%
2008-12-31HK$2.02 B-4.23%
2007-12-31HK$2.11 B52.18%
2006-12-31HK$1.39 B20.73%
2005-12-31HK$1.15 B-4.44%
2004-12-31HK$1.20 B-34.38%
2003-12-31HK$1.83 B6.16%
2002-12-31HK$1.73 B-2.5%
2001-12-31HK$1.77 B102.26%
2000-12-31HK$0.87 B1537.6%
1999-12-31HK$53.6 M

Cash on Hand for similar companies or competitors

Company Cash on Hand differencediff. Country
HK$33.45 B 261.49%๐Ÿ‡ฌ๐Ÿ‡ง UK
HK$56.68 B 512.54%๐Ÿ‡ซ๐Ÿ‡ท France
HK$113.55 B 1,127.17%๐Ÿ‡บ๐Ÿ‡ธ USA
HK$62.98 B 580.65%๐Ÿ‡บ๐Ÿ‡ธ USA
HK$70.11 B 657.76%๐Ÿ‡บ๐Ÿ‡ธ USA
HK$157.94 B 1,606.84%๐Ÿ‡บ๐Ÿ‡ธ USA
HK$77.44 B 736.89%๐Ÿ‡บ๐Ÿ‡ธ USA
HK$0.22 B-97.62%๐Ÿ‡บ๐Ÿ‡ธ USA
HK$0.60 B-93.49%๐Ÿ‡บ๐Ÿ‡ธ USA